Samar Elblehi, Dina Gad El-Karim


Hydroxyurea (HU) is an anti-neoplastic drug which is used for treatment of many types of tumors; however, its wide range of deleterious effects may limit its medical usage. This study was conducted to assess the possible protective role of Panax ginseng extract (Ginseng) against HU- induced hepato-renal damage in rats. Forty male Wistar albino rats were randomly divided into four equal groups (10 rats each). Group I (control) received 1ml purified water. Group II (Ginseng-treated) received 200 mg/kg body weight (b.wt) of Panax ginseng extract. Group III (HU-treated) received HU at a dose of 500 mg/ kg b.wt. Group IV (HU plus ginseng) received HU and Panax ginseng extract in similar doses of group II and III. All the treatments were administrated orally. Treatment with Panax ginseng failed to ameliorate the hematological alterations caused by HU, but, its ability to alleviate hepato-renal cytotoxic effect was proved through significant reduction in plasma level of hepato-renal injury biomarkers (AST, ALT, GGT, urea and creatinine) which were elevated in HU-treated group. Also, this effect was affirmed by decreased level of plasma pro-inflammatory cytokines (TNF-α and IL-6) and enhanced anti-oxidant state (decreased MDA content and increased GPX activity) of hepato-renal tissues upon Panax ginseng extract administration with HU. Histopathologically, HU induced impairments in both hepatic and renal tissues of the treated rats. Conversely, concurrent administration of ginseng with HU partially improved these alterations.

Key words: hydroxyurea; hepato-renal toxicity; Panax ginseng; rats

Full Text:



FDA. Center for Drug Evaluation and Re-search. Hydrea® packet insert.2010 http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/016295s040lbl.pdf.

Marconato L, Bonfanti U, Fileccia I. Unu-sual dermatologic toxicity of hydroxyurea in two dogs with spontaneously occurring tumors. J Sm An Pract2007;48: 514–17.

Rassnick KM, Al–Sarraf R, Bailey DB, Chretin JD, Phillips B Zwhalen CH. Phase II open–label study of single–agent hy-droxyureafor treatment of mast cell tumours in dogs. Vet Comp Oncol 2010; 8: 103–11.

Bunn HF. Pathogenesis and treatment of sickle cell disease. N Eng J Med1997; 337: 762–69.

Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Eng J Med 1995; 332: 1317–22.

Venkayala SL, HargisJC, Woodcock HL.Unlockingthebinding and reaction mecha-nism of hydroxyurea substrates as biological nitric oxide donors. J Chem Info Modeling 2012; 52: 1288–97.

Silva–Pinto AC, Dias–Carlos C, Saldanha–Araujo F, Ferreira FIS, Palma PVB, Araujo AG et al. Hydroxycarbamide modulates compo-nents involved in the regulation of adenosine levels in blood cells from sickle–cell anemia patients. Ann Hematol 2014; 93:1457–65.

Philips FS, Sternberg SS, Schwartz HS, Cronin AP, Sodergren JE, Vidal PM. Hy-droxyurea I. Acute cell death in proliferating tissues in rats.Cancer Res 1967; 27: 61–74.

Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hy-droxyurea. MolPharmacol. 1997; 52(6):1081–6.

Jordan A., Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 1998;67:71–98.

Shao J, Zhou B, Chu B, Yen Y. Ribonu-cleotide reductase inhibitors and future drug design. Curr Cancer Drug Targ 2006; 6:409–31.

Saban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer ChemotherPharmacol 2009; 64: 213–21.

FDA. Center for Drug Evaluation and Research. Droxia® packet insert. 2012 http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016295s041s042lbl.pdf.

Morton D, Reed L, Huang W, Marcek JM, Austin–LaFrance R, Northcott CA et al. Toxicity of Hydroxyurea in Rats and Dogs.ToxicolPathol 2015;43(4):498–512.

Saalu LC, Osinubi AA, Akinbami AA., YamaOE, Oyewopo AO, Enaibe BU. Moringaoleifera Lamarck (drumstick) Leaf Ex-tract Modulates the Evidences of Hydroxyurea –Induced Testicular Derangement. Int J Appli Res Natur Products 2011; 4 (2): 32–45.

Wray JD. Methaemoglobinaemia caused by hydroxycarbamide (hydroxyurea) ingestion in a dog. J Sm An Pract 2008;49: 211–15.

O’Branski EE, Ware RE, Prose NS, Kin-ney TR. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea thera-py. J Am AcadDermato2001; l44: 859–61.

Vassallo C, Passamonti F, AdrigoM,Nolli G, Mangiacavalli S, Boroni G. Muco–cutaneous changes during long–term therapy with hy-droxyurea in chronic myeloid leukemia. Clin-ExpDermatol 2001; 26: 141–48.

Imai H, MatsumuraN, YamazakiY, Ka-nayamaY, MasudaT, KuwakoT, KamideY, TomizawaT, Matsumoto S, MitsuiT, KairaK, OnoA, KogaY, ShibusawaN, SunagaN, Hisa-daT, Yokoo H, Yamada M. Hydroxyurea–induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case. Int Med 2015; 54: 3171–76.

Bargagl IE, Palazz IM, Perri F, Torricel-liE, Rosi E, BindiA, PistolesiM, Voltolini L. Fibrotic Lung Toxicity Induced by Hydroxycar-bamide. In Vivo 2017; 31(6): 1221–23.

Kiefer D., Pantuso T. Panax ginseng. Am Fam Physician. 2003; 68: 1539–1542.

Cho I.H. Effects of Panax ginseng in neurodegenerative diseases. J Ginseng Res. 2012; 36: 342–53.

Ernst E. Panax ginseng: an overview of the clinical evidence. J Ginseng Res. 2010; 34: 259–63.

Park HJ, Kim DH, Park SJ, Kim JM, Ryu JH. Ginseng in traditional herbal prescriptions. J Ginseng Res. 2012; 36:225–41.

Baek SH, Bae ON, Park JH. Recent methodology in ginseng analysis. J Ginseng Res. 2012; 36:119–34.

Choi KT. Botanical characteristics, pharmacological effects and medicinal compo-nents of Korean Panax ginseng CA Meyer. ActaPharmacol Sin. 2008; 29:1109–18.

Park SH, Oh MR, Choi EK, Kim MG, Ha KC, Lee SK, Kim YG, Park BH, Kim DS, Chae SW. An 8–wk, randomized, double–blind, pla-cebo–controlled clinical trial for the antidiabetic effects of hydrolyzed ginseng extract. J Ginseng Res. 2014; 38(4):239–43.

Cha KM, Kopalli SR, Han SY, Lee SH, Jeong MS, Cho JY ha KM, Rajendra KS, Yun HS, Lee SH, Jeong MS, Cho J, Han CG, Lee SH, Kim SN, Kim JC, Kim SK. Korean red gin-seng attenuates doxorubicin–induced testicular dysfunction in rats by modulating inflammato-ry, oxidative, and autophagy responses, J Funct Food 2018; 40:736–43.

Kim SJ, Kim AK. Anti–breast cancer ac-tivity of fine black ginseng (Panax ginseng Meyer) and ginsenoside Rg5. J Ginseng Res 2015; 39(2):125–34.

Chen G, Li H, Zhao Y, Zhu H, Cai E, GaoY,Liu S, Yang H1, Zhang L. Saponins from stems and leaves of Panax ginseng prevent obe-sity via regulating thermogenesis, lipogenesis and lipolysis in high–fat diet–induced obese C57BL/6 mice. Food ChemToxicol 2017; 106(A) 393–403.

Kang S, Min H. Ginseng, the 'Immunity Boost': the effects of Panax ginseng on immune system. J Ginseng Res 2012; 36:354–68.

Kim SJ, Kim AK. Anti–breast cancer ac-tivity of fine black ginseng (Panax ginseng Meyer) and ginsenoside Rg5, J. Ginseng Res 2015; 39(2):125–34

Kalkan Y, Kapakin KA, Kara A, Atabay T, Karadeniz A, Simsek N, Karakus E, Can I, Yildirim S, Ozkanlar S, Sengul E. Protective effect of Panax ginseng against serum biochem-ical changes and apoptosis in kidney of rats treated with gentamicin sulphate. J MolHist 2012; 43(5):603–13.

Nair AB, Jacob S. A simple practice guide for dose conversion betweenanimals and human J Basic Clin Pharma 2016; 7: 27–31.

El–Bayomi K M, Saleh A A, Awad A, El–Tarabany M S, El–Qaliouby H S, Afifi M, El–Komy S, Essawi W M, Almadaly E A, El–Magd M A. Association of CYP19A1 gene pol-ymorphisms with anoestrus in water buffaloes, Reproduction, Fertility and Development 2018; 30(3): 487–97.

SAS. Statistical analysis system. SAS Us-er’s Guide, SAS incorpInst 2004.

Schecheter AN, Rodgers GP. Sickle cell anemia–basic researches reach the clinic. Eng J Med 1995; 332: 1372–74.

Liebelt EL, Balk SJ, Faber W, Fisher JW, Hughes CL, Lanzkron S M. et al. NTP–CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res 2007; 80: 259–366.

Ahmad ME, Shadab GG, Azfer, MA. Ef-fect of oxymetholone on SCE frequency in human lymphocyte chromosomes in vitro. Tera-togen Carcinog Mutagen 2003; 1: 267–72.

Johnson C, Telen MJ. Adhesion Mole-cules And Hydroxyurea In The Pathophysiolo-gy Of Sickle Cell Disease. Haematologica 2008; 93: 481–85.

Iyamu EW, Fasold H, Roa D, del Pilar Aguinaga M, Asakura T, Turner EA. Hy-droxyurea–induced oxidative damage of normal and sickle cell hemoglobins in vitro: ameliora-tion by radical scavengers. J Clinic Lab Anal.2001; 15: 1–7.

Vassort F, Winterholer M, Frinde-lE,Tubiana M. Kinetic Parameters of bone mar-row stem cells Using in vivo Suicide by Tritiat-ed Thymidine or by Hydroxyurea. Blood 1973; 41(6): 789–96.

Malec J, Przybyszewski MW, Grabar-czyk M, Sitarska, E. Hydroxyurea has the ca-pacity to induce damage to human erythrocytes which can be modified by radical scavengers. BiochemBiophys Res Commun1984; 120:566–73.

Farber E, Baserga R. Differential Effects of Hydroxyurea on Survival of Proliferating Cells in Vivo.Cancer Res. 1969; 29(1):136–9.

Sakano k. Oikawa s. Hasegawa K. Ka-wanishi S. Hydroxyurea Induces Site–specific DNA Damage via Formation of Hydrogen Per-oxide and Nitric Oxide. Jpn. J. Cancer Res. 2011; 92: 1166–74.

Nagai T, Tarumoto T, Miyoshi T, Ohmine K, Muroi K, Komatsu N, Sassa S, Ozawa K. Oxidative Stress is Involved in Hy-droxyurea–induced Erythroid Differentiation. British J. of Haematol 2003; 121: 657–61.

Cokic VP, Smith RD, Beleslin–Cokic BB, Njoroge JM, Miller JL, Gladwin MT,Schechter AN. Hydroxyurea induces fetal hemoglobin by the nitric oxide–dependent acti-vation of soluble guanylylcyclase. J clinic in-vest 2003; 111(2): 231–9.

Przybyszewski WM, Malec J. Protection against hydroxyurea–induced cytotoxic effects in L5178Y cells by free radical scavengers. Cancer Lett 1982;17: 223–8.

Grabarczyk M, Przybyszewski WM, Kwiatkowska J, SitarskaE,Malec J. Alteration in lysosome supravital staining as marker ofhy-droxyurea–induced cytotoxicity and its modifi-cation by radical scavengers in L5178Y cells in culture. Neoplasma 1983; 30:541–6.

Yarbro JW. Mechanisms of action of hydroxyurea. SeminOncol 1992; 19:1–10.

Koviac P. Hydroxyurea (therapeutics and mechanism): Metabolism, carbamoylnitroso, nitroxyl, radicals, cell signaling and clinical ap-plications. Med Hypotheses 2011; 76: 24–31.

Latimer KS, Mahaffey EA, Prasse KW. Veterinary Laboratory Medicine, Clinical Pa-thology. 4th ed. Iwoa State Press. USA 2003.

Ahmad MF, Ansari MO, Jameel S, Wani AL, Parveen N, Siddique HR et al. Protective Role of

Nimbolide against Chemotherapeutic Drug Hy-droxyurea Induced Genetic and Oxidative Damage in an Animal Model. Environ Toxicol Pharmacol 2018; 60: 91–9.

Choe WCS, Chung W, Lee SKW, Leung AWN, Cheng CHK, Yue KKM. Ginsenoside Re of Panax Ginseng possesses significant antioxi-dant and antihyperlipidemic efficiencies in strep-tozotocin–induced diabetic rats. Euro J Pharma 2006; 550: 173–9.

Swairess FAR. Effect of Ginseng Extract Supplementation on Renal Functions in Diabetic Rats. J of Agri Sci 2011; 3(2): 17–31.

El–Denshary ES, Al–Gahazali MA, Man-naa FA, Salem HA, Hassan NS, Abdel–Wahhab MA. Dietary honey and ginseng protect against carbon tetrachloride–induced hepato–nephrotoxicity in rats. Exp Toxicol Pathol 2012; 64(7–8): 753–60.

Zhu H, Long MH, Wu J, Wang MM, Li XY, Shen Het al. Ginseng alleviates cyclophos-phamide–induced hepatotoxicity via reversing disordered homeostasis of glutathione and bile acid. Sci Rep. 2015; 5:17536.

Qi ZL, Wang Z, Li W, Hou JG, Liu Y, Li XDet al. Nephroprotective Effects of Anthocy-anin from the Fruits of Panax ginseng (GFA) on Cisplatin–Induced Acute Kidney Injury in Mice. Phytother Res 2017; 31(9):1400–9.

Wang W, Wang S, Liu J, Cai E, Zhu H, He Zet al.Sesquiterpenoids from the root of Panax Ginseng protect CCl4–induced acute liver injury by anti–inflammatory and anti–oxidative capabilities in mice. Biomed Pharma-cother2018; 102: 412–19.

Zhou YD, Hou JG, Liu W, Ren S, Wang YP, Zhang Ret al. 20(R)–ginsenoside Rg3, a rare saponin from red ginseng, ameliorates acet-aminophen–induced hepatotoxicity by sup-pressing PI3K/AKT pathway–mediated inflam-mation and apoptosis. IntImmunopharmacol 2018; 59: 21–30.

DOI: http://dx.doi.org/10.26873/SVR-798-2019


  • There are currently no refbacks.

Gerbičeva 60, SI-1000 Ljubljana, Slovenia, T: +386 (0)1 47 79 100, F: +386 (0)1 28 32 243, E: slovetres@vf.uni-lj.si
Published by computing.si